Infliximab

Key facts

Invented name
Remicade
Active substance
infliximab
Therapeutic area
Gastroentology-Hepatology
Decision number
P/239/2010
PIP number
Infliximab
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
  • Ankylosing spondylitis
  • Juvenile idiopathic arthritis
  • Psoriatic arthritis
  • Rheumatoid arthritis
  • Treatment of Crohn's disease
  • Treatment of psoriasis
  • Treatment of ulcerative colitis
Route(s) of administration
Intravenous use
Contact for public enquiries
Centocor B.V.
info@remicade.eu
The Netherlands
Phone: +31 202015009
Fax: +-*31 713065101
Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000549-PIP01-09-M01
Compliance opinion date
16/09/2011
Compliance outcome
positive

Decision

How useful was this page?

Add your rating
Average
1 rating